TECH Overview

Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.

Wall Street analysts forecast TECH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECH is66.14 USD with a low forecast of 60.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Bio-Techne Corp revenue for the last quarter amounts to 311.42M USD, decreased -1.51

Bio-Techne Corp. EPS for the last quarter amounts to 0.32 USD, increased 128.57

Bio-Techne Corp (TECH) has 3100 emplpoyees as of June 13 2026.

Today TECH has the market capitalization of 8.45B USD.